2008 and earlier
Arnon TI., Kaiser JT., West AP Jr., Olson R., Diskin R., Viertlboeck BC., Göbel TW., Bjorkman PJ., 2008, J. Mol. Biol., 381(4):1012-24 “The crystal structure of CHIR-AB1: a primordial avian classical Fc receptor”. [PubMed]
Diskin R., Engelberg D. and Livnah O., 2008, J. Mol. Biol., 375(1):70-9 “A Novel Lipid Binding Site formed by the MAP Kinase Insert in p38α”. [PubMed]
Avitzour M., Diskin R., Raboy B., Engelberg D. and Livnah O., 2007, FEBS J., 274(4):963-75 “Intrinsically Active Variants of all Human p38 Isoforms”. [PubMed]
Diskin R., Engelberg D. and Livnah O., 2007, Acta Crystallogr. D, 63, 260-265 “High resolution diffracting crystals of intrinsically active p38α MAP kinase: A case study for low-throughput approaches”. [PubMed]
Askari N., Diskin R., Avitzour M., Capone R., Livnah O. and Engelberg D., 2007, J. Biol. Chem., 282(1):91-9 “Hyperactive Variants of p38α Induce Whereas Hyperactive Variants of p38γ Suppress AP-1-Mediated Transcription”. [PubMed]
Diskin R., Lebendiker M., Engelberg D. and Livnah O., 2007, J. Mol. Biol., 365(1):66-76 “Structures of p38α Active Mutants Reveal Conformational Changes in L16 loop that Induce Autophosphorylation and Activation”. [PubMed]
Friedmann Y., Shriki A., Bennett E. R., Golos S., Diskin R., Bengal E. and Engelberg D., 2006, Mol. Pharmacol., 70(4):1395-405 “JX401, a p38α inhibitor, containing a 4-benzylpiperidine motif, identified via a novel screening system in yeast”. [PubMed]
Askari N., Diskin R., Avitzour M., Yaakov G., Livnah O., Engelberg D., 2006, Mol. Cell. Endocrinol., 252(1-2):231-40., “MAP-quest: Could we produce constitutively active variants of MAP kinases?”. [PubMed]
Diskin R., Askari N., Capone R., Engelberg D. and Livnah O., 2004, J. Biol. Chem., 279(45):47040-49 “Active mutants of the p38α Mitogen Activated Protein kinase”. [PubMed]